Alto Neuroscience ANRO ALTO-101 — Direct external program expenses:
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Alto Neuroscience in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Alto Neuroscience’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Alto Neuroscience's alto-101 — direct external program expenses:.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Alto Neuroscience's ALTO-101 — direct external program expenses:?
- Alto Neuroscience (ANRO) reported ALTO-101 — direct external program expenses: of $5.36M in Q1 2026.
- How has Alto Neuroscience's ALTO-101 — direct external program expenses: changed year-over-year?
- Alto Neuroscience's ALTO-101 — direct external program expenses: increased by 452.7% year-over-year, from $969K to $5.36M.
- What is the long-term trend for Alto Neuroscience's ALTO-101 — direct external program expenses:?
- Over 2 years (2023 to 2025), Alto Neuroscience's ALTO-101 — direct external program expenses: has grown at a 69.6% compound annual growth rate (CAGR), from $1.73M to $4.98M.
- What does ALTO-101 — direct external program expenses: mean?
- This metric represents the direct research and development costs specifically attributable to the advancement of the ALTO-101 clinical program. It captures external expenditures such as clinical trial site fees, contract research organization services, and manufacturing costs required to progress the asset through its development lifecycle. Monitoring these expenses provides insight into the capital intensity and resource allocation dedicated to this specific therapeutic candidate.